The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.
The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.
In this conversation, people discussed how Minoxidil and Finasteride can be toxic to cats if ingested. It was highlighted that even when being careful with application, there is still a risk of poisoning due to the potential for contact between fur/hair and the substances.
Hair loss treatments discussed include 200mg Spiro, bicalutamide, and finasteride. Endocrinologist advises against bicalutamide and finasteride due to potency and risks.
People are experimenting with high doses of dutasteride, with some reporting halted hair loss and regrowth. Others are combining it with treatments like minoxidil and finasteride, noting varying results and side effects.
User switched from Fin to Dut for better hair loss results, using 0.5mg Dut and 1ml Min daily. Some discuss potential side effects and benefits of Dut compared to Fin.
A user asked if they can crush caffeine and melatonin tablets to add to their minoxidil solution. Another user sarcastically suggested adding rat poison.
The user is happy with their crown after 2 years on finasteride and topical minoxidil but is still losing hair at the hairline. They plan to switch to dutasteride.
The user has been taking oral Minoxidil (1.25mg/day) for two weeks to treat hair loss, has experienced no side effects, and plans to increase the dose to 2.5mg/day after another two weeks. They are also monitoring their blood pressure and have not noticed any negative interactions with their pre-workout supplements.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.
The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.
User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.
The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.
The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
A 33-year-old male reports slight hair regrowth and improved thickness after 2.5 months using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. Users note slight improvement, especially in the crown area, and suggest patience for more results.
The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.
A user shared a 4-month hair loss progress update using a daily pill containing 1.1mg finasteride, 3mg minoxidil, and biotin, along with weekly Ketoconazole shampoo. They noted significant improvement and advised against using expensive teledoc services.
Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.